We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
In the latest trading session, Astrazeneca (AZN - Free Report) closed at $158.61, marking a +1.33% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.58%. On the other hand, the Dow registered a gain of 0.49%, and the technology-centric Nasdaq increased by 0.45%.
Prior to today's trading, shares of the pharmaceutical had lost 3.79% was narrower than the Medical sector's loss of 4.26% and lagged the S&P 500's gain of 0.84%.
Market participants will be closely following the financial results of Astrazeneca in its upcoming release. The company plans to announce its earnings on October 30, 2026. The company is predicted to post an EPS of $2.16, indicating a 9.24% decline compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $16.07 billion, indicating a 5.82% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of $9.37 per share and a revenue of $63.12 billion, demonstrating changes of +2.29% and +7.46%, respectively, from the preceding year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.29% increase. Right now, Astrazeneca possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Astrazeneca has a Forward P/E ratio of 16.71 right now. This denotes a discount relative to the industry average Forward P/E of 22.46.
Investors should also note that AZN has a PEG ratio of 1.32 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.91 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 179, placing it within the bottom 28% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Astrazeneca (AZN - Free Report) closed at $158.61, marking a +1.33% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.58%. On the other hand, the Dow registered a gain of 0.49%, and the technology-centric Nasdaq increased by 0.45%.
Prior to today's trading, shares of the pharmaceutical had lost 3.79% was narrower than the Medical sector's loss of 4.26% and lagged the S&P 500's gain of 0.84%.
Market participants will be closely following the financial results of Astrazeneca in its upcoming release. The company plans to announce its earnings on October 30, 2026. The company is predicted to post an EPS of $2.16, indicating a 9.24% decline compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $16.07 billion, indicating a 5.82% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of $9.37 per share and a revenue of $63.12 billion, demonstrating changes of +2.29% and +7.46%, respectively, from the preceding year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.29% increase. Right now, Astrazeneca possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Astrazeneca has a Forward P/E ratio of 16.71 right now. This denotes a discount relative to the industry average Forward P/E of 22.46.
Investors should also note that AZN has a PEG ratio of 1.32 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.91 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 179, placing it within the bottom 28% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.